Publicacions en què col·labora amb ISRAEL JOHN THUISSARD VASALLO (29)

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial

    Scientific Reports, Vol. 14, Núm. 1

  3. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  3. Result of the update of the clinical pathway for hip fracture in the older adult at a university hospital in Madrid

    Revista Espanola de Geriatria y Gerontologia, Vol. 58, Núm. 2, pp. 61-67

  4. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  5. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

2022

  1. Accuracy, feasibility and predictive ability of different frailty instruments in an acute geriatric setting

    European Geriatric Medicine, Vol. 13, Núm. 4, pp. 827-835

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  3. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352

2021

  1. Clinical Characteristics, Frailty, and Mortality of Residents With COVID-19 in Nursing Homes of a Region of Madrid

    Journal of the American Medical Directors Association, Vol. 22, Núm. 2, pp. 245-252.e2

  2. Effect of intravenous iron on functional outcomes in hip fracture: A randomised controlled trial

    Age and Ageing, Vol. 50, Núm. 1, pp. 127-134

  3. Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases

    Vaccines, Vol. 9, Núm. 3, pp. 1-12

  4. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

  5. Muscle Assessment by Ultrasonography: Agreement with Dual-Energy X-Ray Absorptiometry (DXA) and Relationship with Physical Performance

    Journal of Nutrition, Health and Aging, Vol. 25, Núm. 8, pp. 956-963

  6. Ras mutational status in advanced colorectal adenocarcinoma treated with anti-angiogenics: Preliminary experience with liquid biopsy

    In Vivo, Vol. 35, Núm. 5, pp. 2841-2844

2020

  1. AB0726 Choroidal Thickness Is a Biomarker a and Can Predict The Response to Treatment in Ankylosing Spondylitis

    Annals of the Rheumatic Diseases, Vol. 79, Núm. Suppl 1, pp. 1657.1-1658

  2. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology

  3. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

    Clinical Rheumatology, Vol. 39, Núm. 9, pp. 2751-2756